Supply Agreement - Share Options

GB00B39J5N63

29 June 2010

                             Scancell Holdings Plc                             

                    ('Scancell Holdings' or the 'Company')                     

                           ICHOR Medical Systems, Inc                            

       Quantification of Share Options under License and Supply Agreement        

Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, announces that, following the Open Offer to shareholders dated 5
March 2010, the options granted to ICHOR Medical Systems Inc ('ICHOR') referred
to in the Open Offer circular relate to a total of 796,156 ordinary shares in
the Company, representing five per cent. of the Company's diluted issued share
capital following the Open Offer. The subscription price payable upon exercise
of the options is 45p (being equal to the price payable under the Open Offer).
The subscription price represents a discount to the closing middle market price
of the Company's ordinary shares on 28 June 2010 of approximately 21.74 per
cent. The options were granted under a License and Supply Agreement ('the
Agreement') dated 13 July 2009 made between Scancell and ICHOR.

Under the terms of the Agreement, ICHOR agreed to supply its TriGridâ„¢
electroporation device for Scancell's pre-clinical and forthcoming clinical
studies with SCIB1 and gave Scancell an option to license TriGridâ„¢ for
commercial use on achievement of certain milestones and payment of royalties.

In return, ICHOR was granted options to subscribe for ordinary shares in the
Company. The options will vest as follows: 159,231 options vest on regulatory
approval being granted to start clinical trials in the UK (which has already
occurred); 318,462 options will vest on starting the first Phase II clinical
trial; and 318,463 options will vest on completing the first Phase II clinical
trial. Each tranche of the options may be exercised at any time in the five
year period after the relevant vesting date.

A copy of this announcement is available for download on the Company's website
at http://www.scancell.co.uk/

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For further information contact:

Professor Lindy Durrant      Scancell Holdings Plc  + 44 (0)207 245 1100    
                                                                            
John Bick/Kirsty Corcoran    Hansard Communications + 44 (0)207 245 1100    
                                                                            
                                                    + 44 (0)7872 061 007    
                                                                            
Ross Andrews/Tom Rowley      Zeus Capital           + 44 (0)161 831 1512    


About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and has recently entered clinical trials.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.